Journal of the Academy of Consultation-Liaison Psychiatry最新文献

{"title":"Psychiatric Adverse Effects of Biologic and Novel Systemic Agents for Psoriasis and Inflammatory Bowel Disease: A Case Series and Literature Review.","authors":"Luis A Velez, Makayla K Portley, Shakaib Khan, Mary Wu Chang, Setareh Alipourfetrati, Mario A Caro","doi":"10.1016/j.jaclp.2025.09.003","DOIUrl":"https://doi.org/10.1016/j.jaclp.2025.09.003","url":null,"abstract":"<p><strong>Background: </strong>Psychiatric symptoms have been reported with certain biologic and novel systemic therapies for psoriasis and inflammatory bowel disease (IBD), but the extent and nature of these effects remain unclear. We summarize the literature and present two illustrative cases to highlight potential associations.</p><p><strong>Methods: </strong>We describe two patients who developed psychiatric symptoms shortly after starting systemic or biologic agents for psoriasis. We then conducted a targeted literature review of PubMed, Embase, and PsycINFO to identify reports of psychiatric adverse effects associated with biological and novel systemic therapies.</p><p><strong>Results: </strong>A review of these databases found 482 results for these agents and psychiatric adverse effects. After excluding duplicate articles and articles that did not mention psychiatric adverse effects, we found 34 articles that described psychiatric adverse effects. There was overall improvement in depressive and anxiety symptoms with the use of biological agents as a class, however, there are case reports of psychiatric adverse effects of these medications. Infliximab, brodalumab, and apremilast have the most evidence regarding psychiatric adverse effects, with brodalumab having a boxed warning for suicidality and apremilast's manufacturer recommending careful monitoring for psychiatric symptoms.</p><p><strong>Conclusions: </strong>Despite improvement in depressive or anxiety symptoms with these agents, psychiatric symptoms may emerge during treatment underscoring the need for careful monitoring. Clinicians should consider individual psychiatric history when selecting immune-modulating therapies for psoriasis and IBD.</p>","PeriodicalId":52388,"journal":{"name":"Journal of the Academy of Consultation-Liaison Psychiatry","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145276563","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"心理学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quality indicators in psychological care for patients with serious illness: A systematic review.","authors":"Takaaki Hasegawa, Toru Okuyama, Ryoichi Sadahiro, Yu Uneno, Yoshiaki Okamoto, Yusuke Kanno, Saho Wada, Shuji Inada, Yuri Igarashi, Hitoshi Tanimukai, Daisuke Fujisawa","doi":"10.1016/j.jaclp.2025.09.002","DOIUrl":"https://doi.org/10.1016/j.jaclp.2025.09.002","url":null,"abstract":"<p><strong>Context: </strong>Psychological care for patients with serious illness is recommended; however, established quality indicators for this care are lacking.</p><p><strong>Objectives: </strong>This study aimed to review clinical quality indicators to evaluate the quality of psychological care for patients with serious illnesses.</p><p><strong>Methods: </strong>This systematic review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. We searched six databases, including MEDLINE, EMBASE, and PsycINFO. Our review included studies on the development of quality indicators for psychological care in patients with serious illness. Study selection and data extraction were conducted independently, and methodological quality was evaluated using the Appraisal of Indicators through Research and Evaluation (AIRE) instrument. The study protocol was registered with the University Hospital Medical Information Network (UMIN000051290).</p><p><strong>Results: </strong>Among the identified 2,119 reports, 345 reports were reviewed in detail and 12 studies met the eligibility criteria. From these, 24 quality indicators were identified, some of which overlapped conceptually or in content: 1 structure, 14 process, and 9 outcome indicators. According to the AIRE instrument, most studies satisfied the category 1 criteria (clarity of purpose, relevance, and organizational context); however, formal validation of the developed indicators in practice was rarely conducted.</p><p><strong>Conclusion: </strong>There is an urgent need for a comprehensive set of validated quality indicators to assess the quality of psychological care across multiple components. Increasing the incorporation of evidence-based psychological care practices for patients with serious illnesses would support the development of valid and useful clinical quality indicators.</p>","PeriodicalId":52388,"journal":{"name":"Journal of the Academy of Consultation-Liaison Psychiatry","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145253774","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"心理学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pazopanib-induced neuropsychiatric symptoms: a case report.","authors":"Wendi Zhao BBiomed, Soumitra Das, Lokesh Sekharan","doi":"10.1016/j.jaclp.2025.09.001","DOIUrl":"https://doi.org/10.1016/j.jaclp.2025.09.001","url":null,"abstract":"","PeriodicalId":52388,"journal":{"name":"Journal of the Academy of Consultation-Liaison Psychiatry","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145240409","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"心理学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Preliminary Characteristics of Telephone-Based Psychiatric Consultations for General Adults Within the CHAMP Program in Indiana.","authors":"Alyssa C Smith, Jon Agley, Camila L Arnaudo, Michael S Metrick","doi":"10.1016/j.jaclp.2025.08.014","DOIUrl":"10.1016/j.jaclp.2025.08.014","url":null,"abstract":"","PeriodicalId":52388,"journal":{"name":"Journal of the Academy of Consultation-Liaison Psychiatry","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145016638","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"心理学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Psychiatric Care Checklist: A Novel Aid to Improve Psychiatric Care in the Emergency Department.","authors":"Obert Xu, Miriam R Elman, Kenneth DeVane, Kendra Henderson, Manny Gonzalez, Haley Manella","doi":"10.1016/j.jaclp.2025.08.013","DOIUrl":"10.1016/j.jaclp.2025.08.013","url":null,"abstract":"<p><strong>Background: </strong>Emergency department (ED) patients requiring inpatient psychiatric admission experience prolonged boarding times due to a nationwide deficit in inpatient bed capacity. These extended boarding times, which can last hours to days, introduce additional risks of harm, including missed home medications and omissions in care essential to chronic disease management. The overall aim is to reduce missed care components in ED patients with psychiatric illness awaiting inpatient psychiatry admission by using our novel checklist and mnemonic, sugar control, home medications, expiration time, documentation, social work, and psychiatry consults, coupled with an educational campaign.</p><p><strong>Objective: </strong>The primary goal of this study was to determine whether the proportion of patients given one or more clinically significant home medications during their ED stay increased after the implementation of the sugar control, home medications, expiration time, documentation, social work, and psychiatry consults checklist and educational interventions.</p><p><strong>Methods: </strong>We performed a retrospective prepost study to evaluate the sugar control, home medications, expiration time, documentation, social work, and psychiatry consults checklist among patients in the ED awaiting placement in an inpatient psychiatric unit. We implemented our psychiatric care checklist as part of a quality improvement campaign through educational messaging and integration into our intradepartmental transition of care note template.</p><p><strong>Results: </strong>We utilized electronic medical record data to compare the proportion of patients with psychiatric illness who received more than one clinically significant home medication before and after the implementation of our interventions. A total of 245 patients were included, consisting of 124 patients seen between March 2022 and February 2023 (preintervention period) and 121 patients between March 2023 and February 2024 (postintervention period). The proportion of patients who received at least one clinically significant home medication in the pre-sugar control, home medications, expiration time, documentation, social work, and psychiatry consults intervention period was 46.0% (95% confidence interval: 37.4-54.8%), compared to 58.7% (95% confidence interval: 49.7-67.1) in the postintervention period. This represents a statistically significant increase in the administration of home medications during the intervention compared to baseline (P < 0.05).</p><p><strong>Conclusions: </strong>This study evaluated the use of a novel psychiatric care checklist in reducing missed home medications in ED patients awaiting inpatient psychiatric admission. The improvement was statistically and clinically significant. Our findings could offer value to other institutions facing significant boarding times for patients with psychiatric illness.</p>","PeriodicalId":52388,"journal":{"name":"Journal of the Academy of Consultation-Liaison Psychiatry","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144994375","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"心理学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hallucinations and Related Perceptual Phenomena in Systemic Lupus Erythematosus and Inflammatory Arthritis: A Cross-sectional Mixed-Methods Study","authors":"Arjoon Arunasalam M.Sc. ,&nbsp;Thomas A. Pollak M.R.C.Psych., Ph.D. ,&nbsp;Avni Varshney M.Sc. ,&nbsp;James A. Bourgeois O.D., M.D. ,&nbsp;David D'Cruz M.D. ,&nbsp;Guy Leschziner M.D., Ph.D. ,&nbsp;Mervi Pitkanen M.R.C. Psych., M.D. ,&nbsp;Alessandra Bortoluzzi M.D., Ph.D. ,&nbsp;Lucy Calderwood B.A. ,&nbsp;Kaira Naidu M.Sc. ,&nbsp;Elaine Dunbar L.L.B. ,&nbsp;Laura Andreoli M.D., Ph.D. ,&nbsp;Martha Piper M.Sc. ,&nbsp;Sydnae Taylor M.Phil. ,&nbsp;Melanie Sloan Ph.D.","doi":"10.1016/j.jaclp.2025.05.005","DOIUrl":"10.1016/j.jaclp.2025.05.005","url":null,"abstract":"<div><h3>Background</h3><div>The INSPIRE (Investigating Neuropsychiatric Symptom Prevalence and Impact in Rheumatology Patient Experiences) research project explored neuropsychiatric symptoms associated with Systemic Autoimmune Rheumatic Diseases (SARDs), identifying hallucinatory experiences as lesser known but impactful symptoms. Following consultations with clinicians and patients, areas of focus included the prevalence, sensory modalities, insight, timings, and emotional valence of hallucinations in SARDs. Our previous research shows that hallucinations and related perceptual phenomena often go unreported and unrecognised in clinical settings with SARD patients.</div></div><div><h3>Objective</h3><div>This study analyses and compares hallucination experiences in patients with systemic lupus erythematosus (SLE) and inflammatory arthritis (IA). We evaluated prevalence, modalities, insight, emotional valence, and timings of hallucinations.</div></div><div><h3>Methods</h3><div>Quantitative data from cross-sectional surveys (n = 1022) and qualitative data from interviews were integrated using mixed methods. Quantitative data are presented descriptively and comparatively (using Pearson's χ² tests), and qualitative data were analyzed thematically.</div></div><div><h3>Results</h3><div>SLE patients reported a greater lifetime prevalence of hallucinations than IA patients, with significant differences in visual (12% vs 6%), olfactory (11% vs 6%), tactile (11% vs 5%), and presence (10% vs 3%) modalities (all <em>P</em> &lt; 0.005). Auditory hallucinations were not significantly more frequent in SLE (8%) than IA (5%) (<em>P</em> = 0.071). Consistent lack of insight into hallucinations was rare (11% of SLE and 4% of IA patients). SLE patients were significantly more likely to experience hallucinations in contexts unrelated to periods of sleep transition than IA patients (<em>P</em> = 0.020). Recognizing hallucinations as SARD symptoms helped patients develop positive coping mechanisms and reduced distress. However, fear of clinician judgment, stigma, and misdiagnoses discouraged reporting.</div></div><div><h3>Conclusions</h3><div>The higher prevalence in SLE likely reflects its greater direct impact of SLE (compared to IA) on the brain. Hallucinatory experiences in SARDs aligned more closely with neurological diseases than primary psychotic disorders. Understanding the varying modalities and contexts of hallucinations as potential direct effects of SLE could improve attribution, treatment, and coping strategies, while reducing stigma and fostering open communication between patients and clinicians.</div></div>","PeriodicalId":52388,"journal":{"name":"Journal of the Academy of Consultation-Liaison Psychiatry","volume":"66 5","pages":"Pages 389-400"},"PeriodicalIF":2.5,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144121522","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"心理学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Paradichlorobenzene Toxicity: A Case Report and Systematic Review of Existing Literature","authors":"Abigail Clark M.D. ,&nbsp;Jordan Hildenbrand M.D. ,&nbsp;Lauren Gensler M.D. ,&nbsp;Nathan Scheiner M.D.","doi":"10.1016/j.jaclp.2025.06.008","DOIUrl":"10.1016/j.jaclp.2025.06.008","url":null,"abstract":"<div><h3>Background</h3><div>Paradichlorobenzene (PDCB) is an active ingredient in mothballs and toilet bowl deodorizers. When PCDB is ingested, acutely or chronically, toxicity involving multiple organ systems, including the brain, kidney, liver, and skin, may result.</div></div><div><h3>Case Report</h3><div>A 32-year-old woman was admitted to a specialized medical and psychiatric inpatient unit with subacute cognitive decline, a diffuse ichthyotic rash, hyperreflexia, bowel and bladder incontinence, and upper extremity rigidity. Initial extensive serum, cerebral spinal fluid, and urine testing was only notable for iron deficiency anemia. Magnetic resonance imaging of the brain revealed periventricular leukoencephalopathy. Collateral was then sought from her spouse, who disclosed she had been ingesting toilet bowel deodorizers for over a year before presentation. Subsequent serum and urine PDCB concentrations were elevated, and the patient was diagnosed with PDCB toxicity. She was provided supportive care, but ultimately, she developed severe cognitive decline, requiring a gastrostomy tube for nutritional support and was discharged to a skilled nursing facility. Her condition was unchanged 6 months after discharge.</div></div><div><h3>Literature review</h3><div>We performed a systematic review of all reported cases of PDCB toxicity in humans; we queried PychINFO, Cumulative Index to Nursing and Allied Health Literature, Web of Science, and OVID/Medline, identifying 18 relevant records of PDCB toxicity. Our review revealed that PDCB toxicity often results in significant but nonspecific neuropsychiatric, skin, and neuroimaging findings. Young women with iron deficiency anemia and substance use histories appear to be at particular risk of PDCB toxicity, though more research is needed to clarify these associations.</div></div><div><h3>Conclusions</h3><div>Clinicians should maintain a high degree of suspicion for toxic ingestion and perform thorough collection of collateral history when the cause of encephalopathy is unknown. Greater attention should also be given to PDCB as a substance of abuse.</div></div>","PeriodicalId":52388,"journal":{"name":"Journal of the Academy of Consultation-Liaison Psychiatry","volume":"66 5","pages":"Pages 440-450"},"PeriodicalIF":2.5,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144509360","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"心理学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Management of Relapsing Catatonia After Lorazepam Discontinuation: A Systematic Review of Published Case Reports","authors":"Olivia Brown Ph.D.,&nbsp;Linda McLay M.Sc.,&nbsp;Paul Glue M.D.,&nbsp;Yoram Barak M.D., M.H.A.","doi":"10.1016/j.jaclp.2025.06.007","DOIUrl":"10.1016/j.jaclp.2025.06.007","url":null,"abstract":"<div><h3>Background</h3><div><span>Lorazepam is the mainstay of pharmacological treatment of </span>catatonia<span>. It is recommended that lorazepam, when effective, be tapered and gradually stopped depending upon maintenance of clinical improvement. This recommendation is not supported by any controlled studies. There are case reports on relapses of catatonia while tapering lorazepam; these patients required long-term maintenance treatment for sustained symptomatic management.</span></div></div><div><h3>Objective</h3><div>This is a review of published literature focusing on relapse of catatonia following lorazepam discontinuation after maintenance treatment.</div></div><div><h3>Methods</h3><div>A comprehensive literature search, with full-text review and data extraction, was undertaken for eligible studies following screening of titles and abstracts. After review, 18 full texts describing 47 individual patients, were analyzed.</div></div><div><h3>Results</h3><div>Forty-seven individual patients are described; age range: 14 to 74 years, with nearly equal numbers of males and females. The common psychiatric comorbidity was a psychotic episode (mostly relapse of schizophrenia). Medical comorbidity was less common, with 31 of 47 patients having no comorbid medical condition. Treatment descriptions were at times missing specific information. No firm conclusions could be drawn from the literature about the length of maintenance, lorazepam dose, or discontinuation parameters.</div></div><div><h3>Conclusions</h3><div>The absence<span> of trials and prospective studies, and the sparsity of details for many of the published case series and case studies, highlight the need for further research in the catatonia field. At present, we propose gradual tapering of lorazepam once catatonia and the underlying illness have been fully treated and a maintenance lorazepam regimen is established, in line with existing benzodiazepine discontinuation guidelines, to minimize the risk of catatonia re-emergence.</span></div></div>","PeriodicalId":52388,"journal":{"name":"Journal of the Academy of Consultation-Liaison Psychiatry","volume":"66 5","pages":"Pages 429-439"},"PeriodicalIF":2.5,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144369533","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"心理学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bidirectional Association Between Peripheral Vestibular Disorders and Depressive Disorders: A Longitudinal Follow-Up Study","authors":"Sheue-Jane Hou M.D. ,&nbsp;Shun-Chieh Yu M.D. ,&nbsp;Shih-Jen Tsai M.D. ,&nbsp;Tzeng-Ji Chen M.D., PH.D ,&nbsp;Mu-Hong Chen M.D., PH.D","doi":"10.1016/j.jaclp.2025.07.001","DOIUrl":"10.1016/j.jaclp.2025.07.001","url":null,"abstract":"<div><h3>Background</h3><div>An increasing body of evidence indicates that peripheral vestibular disorders (PVDs) are associated with depressive disorders. However, further investigation is required to elucidate the temporal and causal relationships between the aforementioned disorders.</div></div><div><h3>Objective</h3><div>To clarify the bidirectional association between peripheral vestibular disorders and depressive disorders.</div></div><div><h3>Methods</h3><div>The present retrospective cohort study used data from the Taiwan National Health Insurance Research Database for the period from January 1, 1998, to December 31, 2013. The study examined PVD and its subtypes as both the cause and consequence of depressive disorders. We collected data from patients diagnosed with either PVDs (<em>N</em> = 87,277) or depressive disorders (<em>N</em> = 87,387) between 1998 and 2011 and from their corresponding controls (1:2 ratio). Cox regression models were employed to evaluate the likelihood of developing depressive disorders or PVDs in patients with prior PVDs or depressive disorders, respectively.</div></div><div><h3>Results</h3><div>Patients with PVDs had a 4.29-fold (95% confidence interval: 3.93–4.68) higher risk of developing depression. Subgroup analyses based on PVD subtypes revealed that all 4 PVD subtypes (benign paroxysmal positional vertigo, Meniere's disease, vestibular neuritis, and unspecified PVD) predicted higher risks of depressive disorders (hazard ratio: 3.89–5.18). Similarly, individuals with depressive disorders exhibited a 3.29-fold (95% confidence interval: 3.05–5.13) higher risk of developing PVDs.</div></div><div><h3>Conclusions</h3><div>The 2 cohort studies revealed a bidirectional relationship between PVDs and depression. Further research is required to establish if these 2 conditions have common pathogenic mechanisms and if treating one effectively reduces the morbidity rate of the other.</div></div>","PeriodicalId":52388,"journal":{"name":"Journal of the Academy of Consultation-Liaison Psychiatry","volume":"66 5","pages":"Pages 409-416"},"PeriodicalIF":2.5,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144638667","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"心理学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Management of Agitation in Frontotemporal Brain Sagging Syndrome: A Case Report","authors":"Sara Friedman M.D., M.P.H.,&nbsp;Jaimie Lynn Rogner M.D., M.P.H.,&nbsp;Diana Punko M.D., M.S.","doi":"10.1016/j.jaclp.2025.08.003","DOIUrl":"10.1016/j.jaclp.2025.08.003","url":null,"abstract":"","PeriodicalId":52388,"journal":{"name":"Journal of the Academy of Consultation-Liaison Psychiatry","volume":"66 5","pages":"Pages 464-465"},"PeriodicalIF":2.5,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144812665","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"心理学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}